Barclays’s Benitec Biopharma BNTC Stock Holding History

Barclays’s Portfolio BNTC Stock Details BNTC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$45.7K	Sell	3,415 -420	-11%	-$4.98K	﹤0.01%	4348
2026 Q1	$40.8K	Sell	3,835 -19,376	-83%	-$224K	﹤0.01%	4390
2025 Q4	$313K	Buy	23,211 +1,928	+9%	+$26.7K	﹤0.01%	4111
2025 Q3	$299K	Sell	21,283 -5,657	-21%	-$72.2K	﹤0.01%	4104
2025 Q2	$315K	Buy	+26,940	New	+$377K	﹤0.01%	4025
2022 Q3	–	Sell	-8,018	Closed	-$158K	–	4801
2022 Q2	$158K	Buy	8,018 +4,565	+132%	+$106K	﹤0.01%	3559
2022 Q1	$137K	Buy	+3,453	New	+$143K	﹤0.01%	3632

Other funds holding BNTC

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SAM

Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

IAM

Infinitum Asset Management Fort Lauderdale, Florida $983M AUM 26.53% 1-Year Est. Return

Barclays's BNTC Position: Q2 2026 in Review

Barclays reduced its Benitec Biopharma (BNTC) stake by 11% in Q2 2026, selling an estimated $4.98K and leaving 3,415 shares worth $45.7K. The position accounts for ﹤0.01% of the portfolio, ranked #4348.

Barclays first reported a position in BNTC in Q1 2022 and has held it in 7 quarters since. The position peaked at $315K in Q2 2025. 87 funds tracked by Wall St. Rank hold BNTC as of Q2 2026.

Barclays held 3,415 shares of Benitec Biopharma worth $45.7K as of Q2 2026.
Barclays sold 420 Benitec Biopharma shares in Q2 2026, an estimated $4.98K.
Benitec Biopharma made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #4348 holding.
Barclays first reported a position in Benitec Biopharma in Q1 2022 and has held it in 7 quarters since.
Barclays's Benitec Biopharma position peaked at $315K in Q2 2025.
87 funds tracked by Wall St. Rank held Benitec Biopharma as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.